Localized ovarian cancer: Surgery plus chemotherapy

Mario V. Fiorentino, Ornella Nicoletto, Pietro de Besi, Giampietro Stefani, Flavio Tredese, Orazio Vinante, Adriano Fornasiero, Attilio Cecchetto, Tiziano Maggino, Diego Marchesoni, Giovanni Nardelli, Antonio Onnis

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Fifty-four patients were referred to Medical Oncology after operation for "limited" ovarian cancer; 7 were excluded because immediate restaging showed evidence of macroscopic spread to structures outside the true pelvis, and 10 will be considered separately because of microscopic spread shown only by cytology. Thirty-seven patients (31 stage I and 6 stage II) were accordingly accepted as "localized", because peritoneal cytology and diaphragm and omental plus parietal peritoneum histology could rule out the spread to the large abdominal cavity. Some of the referred patients had been operated in nearby hospitals; the Padua GYN Cin. performed 14 of the 37 first surgery operations and 30 of the 37 second look operations. All patients soon after surgery underwent first-line chemotherapy with 5 courses of high dose adriamycin plus cyclophosphamide for 4 months, then surgical second look, and second-line non-cross-resistant chemotherapy for 3 months. During the second look the organ and tissue removal was completed in those 21 patients having received "limited" first surgery. Two patients died within 5 years from admission, so that the overall 5 year actuarial survival from referral is 93% for the entire group with 11 patients still at risk; 87% are disease free 5 years after the second look with 7 at risk. Subdivision of the patients according to "adequate" vs. "limited" first surgery, may select a group (the "adequate" one, composed of 16 patients) completely free from relapses, up to now. The complex therapeutic program described seems to offer long term relapse-free survival to the majority of patients, while the few failures seem closely related with inadequacies of the initial surgical procedure.

Original languageEnglish
Pages (from-to)1365-1370
Number of pages6
JournalEuropean Journal of Cancer and Clinical Oncology
Volume22
Issue number11
DOIs
Publication statusPublished - 1986

Fingerprint

Ovarian Neoplasms
Drug Therapy
Cell Biology
Lesser Pelvis
Recurrence
Survival
Medical Oncology
Abdominal Cavity
Peritoneum
Diaphragm
Doxorubicin
Cyclophosphamide
Histology
Referral and Consultation

ASJC Scopus subject areas

  • Oncology

Cite this

Fiorentino, M. V., Nicoletto, O., de Besi, P., Stefani, G., Tredese, F., Vinante, O., ... Onnis, A. (1986). Localized ovarian cancer: Surgery plus chemotherapy. European Journal of Cancer and Clinical Oncology, 22(11), 1365-1370. https://doi.org/10.1016/0277-5379(86)90146-X

Localized ovarian cancer : Surgery plus chemotherapy. / Fiorentino, Mario V.; Nicoletto, Ornella; de Besi, Pietro; Stefani, Giampietro; Tredese, Flavio; Vinante, Orazio; Fornasiero, Adriano; Cecchetto, Attilio; Maggino, Tiziano; Marchesoni, Diego; Nardelli, Giovanni; Onnis, Antonio.

In: European Journal of Cancer and Clinical Oncology, Vol. 22, No. 11, 1986, p. 1365-1370.

Research output: Contribution to journalArticle

Fiorentino, MV, Nicoletto, O, de Besi, P, Stefani, G, Tredese, F, Vinante, O, Fornasiero, A, Cecchetto, A, Maggino, T, Marchesoni, D, Nardelli, G & Onnis, A 1986, 'Localized ovarian cancer: Surgery plus chemotherapy', European Journal of Cancer and Clinical Oncology, vol. 22, no. 11, pp. 1365-1370. https://doi.org/10.1016/0277-5379(86)90146-X
Fiorentino, Mario V. ; Nicoletto, Ornella ; de Besi, Pietro ; Stefani, Giampietro ; Tredese, Flavio ; Vinante, Orazio ; Fornasiero, Adriano ; Cecchetto, Attilio ; Maggino, Tiziano ; Marchesoni, Diego ; Nardelli, Giovanni ; Onnis, Antonio. / Localized ovarian cancer : Surgery plus chemotherapy. In: European Journal of Cancer and Clinical Oncology. 1986 ; Vol. 22, No. 11. pp. 1365-1370.
@article{0e0edf38c0314564b294e1fe44d76fbf,
title = "Localized ovarian cancer: Surgery plus chemotherapy",
abstract = "Fifty-four patients were referred to Medical Oncology after operation for {"}limited{"} ovarian cancer; 7 were excluded because immediate restaging showed evidence of macroscopic spread to structures outside the true pelvis, and 10 will be considered separately because of microscopic spread shown only by cytology. Thirty-seven patients (31 stage I and 6 stage II) were accordingly accepted as {"}localized{"}, because peritoneal cytology and diaphragm and omental plus parietal peritoneum histology could rule out the spread to the large abdominal cavity. Some of the referred patients had been operated in nearby hospitals; the Padua GYN Cin. performed 14 of the 37 first surgery operations and 30 of the 37 second look operations. All patients soon after surgery underwent first-line chemotherapy with 5 courses of high dose adriamycin plus cyclophosphamide for 4 months, then surgical second look, and second-line non-cross-resistant chemotherapy for 3 months. During the second look the organ and tissue removal was completed in those 21 patients having received {"}limited{"} first surgery. Two patients died within 5 years from admission, so that the overall 5 year actuarial survival from referral is 93{\%} for the entire group with 11 patients still at risk; 87{\%} are disease free 5 years after the second look with 7 at risk. Subdivision of the patients according to {"}adequate{"} vs. {"}limited{"} first surgery, may select a group (the {"}adequate{"} one, composed of 16 patients) completely free from relapses, up to now. The complex therapeutic program described seems to offer long term relapse-free survival to the majority of patients, while the few failures seem closely related with inadequacies of the initial surgical procedure.",
author = "Fiorentino, {Mario V.} and Ornella Nicoletto and {de Besi}, Pietro and Giampietro Stefani and Flavio Tredese and Orazio Vinante and Adriano Fornasiero and Attilio Cecchetto and Tiziano Maggino and Diego Marchesoni and Giovanni Nardelli and Antonio Onnis",
year = "1986",
doi = "10.1016/0277-5379(86)90146-X",
language = "English",
volume = "22",
pages = "1365--1370",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "11",

}

TY - JOUR

T1 - Localized ovarian cancer

T2 - Surgery plus chemotherapy

AU - Fiorentino, Mario V.

AU - Nicoletto, Ornella

AU - de Besi, Pietro

AU - Stefani, Giampietro

AU - Tredese, Flavio

AU - Vinante, Orazio

AU - Fornasiero, Adriano

AU - Cecchetto, Attilio

AU - Maggino, Tiziano

AU - Marchesoni, Diego

AU - Nardelli, Giovanni

AU - Onnis, Antonio

PY - 1986

Y1 - 1986

N2 - Fifty-four patients were referred to Medical Oncology after operation for "limited" ovarian cancer; 7 were excluded because immediate restaging showed evidence of macroscopic spread to structures outside the true pelvis, and 10 will be considered separately because of microscopic spread shown only by cytology. Thirty-seven patients (31 stage I and 6 stage II) were accordingly accepted as "localized", because peritoneal cytology and diaphragm and omental plus parietal peritoneum histology could rule out the spread to the large abdominal cavity. Some of the referred patients had been operated in nearby hospitals; the Padua GYN Cin. performed 14 of the 37 first surgery operations and 30 of the 37 second look operations. All patients soon after surgery underwent first-line chemotherapy with 5 courses of high dose adriamycin plus cyclophosphamide for 4 months, then surgical second look, and second-line non-cross-resistant chemotherapy for 3 months. During the second look the organ and tissue removal was completed in those 21 patients having received "limited" first surgery. Two patients died within 5 years from admission, so that the overall 5 year actuarial survival from referral is 93% for the entire group with 11 patients still at risk; 87% are disease free 5 years after the second look with 7 at risk. Subdivision of the patients according to "adequate" vs. "limited" first surgery, may select a group (the "adequate" one, composed of 16 patients) completely free from relapses, up to now. The complex therapeutic program described seems to offer long term relapse-free survival to the majority of patients, while the few failures seem closely related with inadequacies of the initial surgical procedure.

AB - Fifty-four patients were referred to Medical Oncology after operation for "limited" ovarian cancer; 7 were excluded because immediate restaging showed evidence of macroscopic spread to structures outside the true pelvis, and 10 will be considered separately because of microscopic spread shown only by cytology. Thirty-seven patients (31 stage I and 6 stage II) were accordingly accepted as "localized", because peritoneal cytology and diaphragm and omental plus parietal peritoneum histology could rule out the spread to the large abdominal cavity. Some of the referred patients had been operated in nearby hospitals; the Padua GYN Cin. performed 14 of the 37 first surgery operations and 30 of the 37 second look operations. All patients soon after surgery underwent first-line chemotherapy with 5 courses of high dose adriamycin plus cyclophosphamide for 4 months, then surgical second look, and second-line non-cross-resistant chemotherapy for 3 months. During the second look the organ and tissue removal was completed in those 21 patients having received "limited" first surgery. Two patients died within 5 years from admission, so that the overall 5 year actuarial survival from referral is 93% for the entire group with 11 patients still at risk; 87% are disease free 5 years after the second look with 7 at risk. Subdivision of the patients according to "adequate" vs. "limited" first surgery, may select a group (the "adequate" one, composed of 16 patients) completely free from relapses, up to now. The complex therapeutic program described seems to offer long term relapse-free survival to the majority of patients, while the few failures seem closely related with inadequacies of the initial surgical procedure.

UR - http://www.scopus.com/inward/record.url?scp=0022970741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022970741&partnerID=8YFLogxK

U2 - 10.1016/0277-5379(86)90146-X

DO - 10.1016/0277-5379(86)90146-X

M3 - Article

C2 - 3830218

AN - SCOPUS:0022970741

VL - 22

SP - 1365

EP - 1370

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 11

ER -